Lisanti Capital Growth LLC Acquires 57,090 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

Lisanti Capital Growth LLC lifted its holdings in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 143.3% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 96,935 shares of the company's stock after buying an additional 57,090 shares during the period. Lisanti Capital Growth LLC owned about 0.25% of Tarsus Pharmaceuticals worth $5,367,000 at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. Creative Planning bought a new position in shares of Tarsus Pharmaceuticals in the 3rd quarter valued at about $362,000. Harbor Capital Advisors Inc. grew its stake in Tarsus Pharmaceuticals by 57.5% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 18,105 shares of the company's stock valued at $595,000 after buying an additional 6,612 shares during the last quarter. GSA Capital Partners LLP bought a new position in Tarsus Pharmaceuticals in the 3rd quarter valued at about $740,000. Mutual of America Capital Management LLC bought a new stake in shares of Tarsus Pharmaceuticals during the third quarter worth approximately $4,291,000. Finally, Jennison Associates LLC grew its position in shares of Tarsus Pharmaceuticals by 47.2% in the third quarter. Jennison Associates LLC now owns 2,178,580 shares of the company's stock valued at $71,653,000 after purchasing an additional 698,712 shares during the last quarter. Institutional investors own 90.01% of the company's stock.

Tarsus Pharmaceuticals Price Performance

NASDAQ:TARS traded up $2.56 during mid-day trading on Tuesday, reaching $47.15. The stock had a trading volume of 554,365 shares, compared to its average volume of 639,616. The stock has a 50-day simple moving average of $49.77 and a two-hundred day simple moving average of $44.14. The company has a debt-to-equity ratio of 0.30, a current ratio of 5.42 and a quick ratio of 5.38. Tarsus Pharmaceuticals, Inc. has a 12 month low of $20.08 and a 12 month high of $57.28. The stock has a market capitalization of $1.81 billion, a PE ratio of -12.38 and a beta of 1.05.

Remove Ads

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last announced its quarterly earnings results on Tuesday, February 25th. The company reported ($0.60) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.68) by $0.08. The company had revenue of $66.41 million for the quarter, compared to analyst estimates of $58.80 million. Tarsus Pharmaceuticals had a negative net margin of 103.64% and a negative return on equity of 55.86%. On average, equities analysts anticipate that Tarsus Pharmaceuticals, Inc. will post -3.17 earnings per share for the current year.

Analyst Ratings Changes

Several analysts recently weighed in on TARS shares. The Goldman Sachs Group lifted their price target on Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the stock a "neutral" rating in a report on Friday, November 15th. Oppenheimer boosted their target price on shares of Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the company an "outperform" rating in a research report on Wednesday, January 22nd. HC Wainwright reaffirmed a "buy" rating and set a $73.00 price target on shares of Tarsus Pharmaceuticals in a research report on Wednesday, February 26th. Barclays cut their price objective on shares of Tarsus Pharmaceuticals from $62.00 to $60.00 and set an "overweight" rating for the company in a report on Wednesday, February 26th. Finally, Jefferies Financial Group raised their target price on shares of Tarsus Pharmaceuticals from $54.00 to $58.00 and gave the stock a "buy" rating in a report on Thursday, March 6th. One equities research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Buy" and an average target price of $63.67.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.